Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Bright Minds Biosciences Inc. C.DRUG

Alternate Symbol(s):  DRUG

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (CSE:DRUG)

Fundamentals Snapshot (CSE:DRUG)

Opinion & Analysis (CSE:DRUG)

No current opinion is available.

Bullboard Posts (CSE:DRUG)

Upcoming catalysts

The next couple of catalysts include the toxicology study for 5HT2A to treat MDD/TRD and the Phase-1 clinical trials for BMB-101 to treat...
Whitman19 - April 13, 2022

RE:Bright Minds Moves Into Clinical Development Stage Following

That's wonderful. Just waiting for the stock to take off
Whitman19 - March 25, 2022

Bright Minds Moves Into Clinical Development Stage Following

Drug development continues for the Bright Minds Biosciences lead product. The firm this morning published positive results from a...
AwareInvestor - March 14, 2022

BMB-101 is all set to hit the clinic in H1’22

Unlike most biotechs developing drugs from naturally occurring psychedelics, Bright Minds is creating novel compounds that retain the...
Whitman19 - January 10, 2022


"I would say we have the largest and most advanced psychedelic drug discovery program in the history of the world. That’s over 25...
Whitman19 - December 29, 2021

BMB: The next-gen psychedelics to treat neuro conditions

Bright Minds has a portfolio of three patented mechanisms based on serotonin (5-HT) receptors, assessed for indications ranging from...
Whitman19 - December 2, 2021